Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression

Exclusion Criteria

• •Patients who participate in another interventional study
• •Patients with known allergy to one or more of the study medications, or to any medication from the non-steroidal anti-inflammatory drug group or beta-blockers family
• •Patients treated chronically with any type of a beta-adrenergic blocker or a COX inhibitor, except use of Aspirin, which will be discontinued at least 7 days prior to surgery, and until 3 weeks post-surgery
• •Patients currently suffering from asthma (אסתמה פעילה בלבד), or required hospital admission or change in medical treatment for asthma within the past year
• •Patients with active peptic disease
• •Patients with a history of CVA/TIA
• •Recent (within the last 5 years) or concurrent malignancies, with the exception of adequately treated in-situ carcinoma of the cervix or basal-cell carcinoma of the skin
• •Patients with renal failure, measured by creatinine level \>1.5
• •Patients with significant liver dysfunction (known cirrhosis, Bilirubin level\>2)
• •Patients with significant heart failure (NYHA functional class 3 or Higher)
• •Patients with bradycardia (heart rate of 50 or less) or second- or third-degree AV block
• •Patients with right-sided heart failure owing to pulmonary hypertension
• •Patients with chronic Digoxin treatment
• •Patients with Printzmetal's angina
• •Patients with significant diagnosed cardiomegaly
• •Patients suffering from sick sinus syndrome
• •Patients with peripheral vascular disease
• •Patients with current (unresected) pheochromocytoma
• •Pregnant women
• •Patients who are treated with immunosuppressive medications, including chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial drug
• •Patients with Immunodeficiency Disorders